Penicillin dosing for pneumococcal pneumonia

被引:36
作者
Bryan, CS
Talwani, R
Stinson, S
机构
[1] UNIV S CAROLINA,SCH MED,DEPT MED,COLUMBIA,SC 29208
[2] RICHLAND MEM HOSP,COLUMBIA,SC
关键词
D O I
10.1378/chest.112.6.1657
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Most textbook authors still endorse penicillin G as the specific antibiotic of choice for pneumococcal pneumonia. However, problems with early precise etiologic diagnosis of pneumonia and the emergence of drug-resistant pneumococci cause penicillin to be seldom used for this purpose today. A third explanation for the infrequent use of penicillin is lack of clear consensus dosing guidelines. Emergence of pneumococci resistant to the newer cephalosporins and concerns about overuse of vancomycin, however, have prompted renewed interest in the development of precise, rapid methods for diagnosis of pneumococcal pneumonia with the implication that penicillin might be used more frequently. We review several issues concerning penicillin dosing: intermittent vs continuous therapy, high dose vs low dose, relationship of dose to resistance, and cost-effective pharmacology. An optimum ''high-dose'' regimen for life-threatening pneumococcal pneumonia in a 70-kg adult consists of a 3 million unit (mu) loading dose followed by continuous infusion of 10 to 12 mu of freshly prepared drug every 12 h. The maintenance dose should he reduced in elderly patients and in patients with renal failure according to the following formula: dose (mu/24 h=4+[creatinine clearance divided by 7]). This regimen provides a penicillin serum level of 16 to 20 mu g/mL, which should suffice for all but the most highly resistant strains (minimum inhibitory concentration greater than or equal to 4 mu g/mL). Newer cephalosporins and vancomycin can be reserved for patients with suspected meningitis or endocarditis or for localities in which highly resistant pneumococci are known to be prevalent.
引用
收藏
页码:1657 / 1664
页数:8
相关论文
共 99 条
  • [51] JACOBS MR, 1995, REV MED MICROBIOL, V6, P77
  • [52] JAWETZ E, 1946, ARCH INTERN MED, V77, P1, DOI 10.1001/archinte.1946.00210360006001
  • [53] Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP) - A strategy from the DRSP Working Group
    Jernigan, DB
    Cetron, MS
    Breiman, RF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (03): : 206 - 209
  • [54] JOHNSON CC, 1994, PYOGENIC BACTERIAL P, P1036
  • [55] KAMPMANN J, 1972, CLIN PHARMACOL THER, V13, P516
  • [56] KUNIN CM, 1981, REV INFECT DIS, V3, P4
  • [57] KUNIN CM, 1961, P SOC EXP BIOL MED, V107, P337, DOI 10.3181/00379727-107-26618
  • [58] ON PENICILLIN LEVELS IN YOUNG AND GERIATRIC SUBJECTS
    LEIKOLA, E
    VARTIA, KO
    [J]. JOURNALS OF GERONTOLOGY, 1957, 12 (01): : 48 - 52
  • [59] LIPCHIK RJ, 1996, TXB PRIMARY CARE MED, P1531
  • [60] MANDEL GL, 1995, PRINCIPLES PRACTICE, P77